C4 Therapeutics Reports Q3 2026 Financial Results with EPS Beat and Revenue Miss
C4 Therapeutics (CCCC) reported third-quarter financial results for the period ending in 2026, characterized by a narrow beat on earnings per share despite a decline in top-line revenue. The company posted a GAAP EPS of -$0.16, surpassing analyst expectations by $0.04. Revenue for the quarter reached $8.5 million, representing a 25.2% year-over-year decrease compared to $11.2 million in the third quarter of 2025. The reported revenue fell slightly short of consensus estimates by $0.12 million.
Tickers: $CCCC
Topics: earnings beat financial results GAAP EPS revenue miss